Delivery Order SPE2DB20D3104-SPE2DB25FV9Q6
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $9,727.53 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on August 12, 2025, with completion due by August 13, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued competitively under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,963.10 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 mL pens on August 7, 2025, with completion expected by August 8, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used for weight management and represents part of the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Zepbound 5 mg/0.5 ml pens with a ceiling value of $2,726.72. This is a firm fixed-price delivery order with an ultimate completion date of July 30, 2025, and represents a non-set-aside competitive award. The product will be delivered to the company's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,325.14 for Zepbound 5 mg/0.5 ml pens on August 15, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management, representing one of many...
- The Defense Logistics Agency awarded a Delivery Order valued at $10,288.27 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injectors. This competitively awarded contract, utilizing firm fixed pricing with no set-aside designation, calls for delivery by August 8, 2025, to the contractor's facility in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication commonly prescribed for weight management and metabolic health support....
- The Defense Logistics Agency awarded a delivery order valued at $9,371.22 to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 ml pen injections on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management and represents...
- The Defense Logistics Agency awarded a delivery order valued at $8,512.52 to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Zepbound 5 mg/0.5 mL pens. This firm fixed-price, non-competitive set-aside delivery order is scheduled for completion by July 29, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management, representing part of the federal government's pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $42,562.60 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pens on July 30, 2025, with completion targeted for July 31, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management, reflecting the federal government's...
- The Defense Logistics Agency has awarded a delivery order valued at $9,307.19 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 mL pens. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under the company's existing indefinite delivery contract. The contract requires delivery by August 18, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a branded GLP-1 receptor...
- The Defense Logistics Agency awarded a delivery order valued at $28,363.85 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen injectors on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Zepbound, a GLP-1 receptor agonist medication used for weight management, represents...
- SPE2DB20D3104Indefinite Delivery Contract
- SPE2DB20D3104-SPE2DB25FV9Q6Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,495.76 to AmerisourceBergen Drug Corp for the supply of Zepbound 15 mg/0.5 mL pens on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used for chronic weight management, representing specialized pharmaceutical inventory needed to support military and federal healthcare operations. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor, AmerisourceBergen Drug Corp maintains a comprehensive portfolio of federal medical supply contracts with the Defense Logistics Agency, supplying an extensive range of brand-name and generic medications, vaccines, and medical supplies to support Defense Health Agency and military healthcare systems worldwide. The company's consistent success in competitive federal procurements demonstrates its established capability to meet complex pharmaceutical supply chain requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.5k | 8/19/25 |